Statement of Principles concerning gout (Reasonable Hypothesis) (No. 59 of 2019)

This instrument, the Repatriation Medical Authority Statement of Principles concerning gout (Reasonable Hypothesis) (No. 59 of 2019), is a medical‑evidentiary instrument made under subsection 196B(2) of the Veterans' Entitlements Act 1986 (VEA) (see s3). It commenced on 27 May 2019 (s2) and repealed the prior Statement of Principles concerning gout No. 30 of 2010 (s4). The instrument applies to claims to which section 120A of the VEA or section 338 of the Military Rehabilitation and Compensation Act 2004 (MRCA) applies (s5). In short, it is a statutory list of medical and non‑medical factors which the Repatriation Medical Authority (RMA) prescribes as the minimum factors that must exist before “it can be said that a reasonable hypothesis has been raised connecting gout or death from gout with the circumstances of a person's relevant service” (s9).

Mechanically, the instrument does three things. First, it defines the meaning of “gout” for the purposes of these claims (s7(2) and s7(3)), and confirms that death from gout includes death from a terminal event or condition that was contributed to by the person’s gout (s7(5)). Second, it states the RMA’s view that sound medical‑scientific evidence indicates gout and death from gout can be related to relevant service (s8), which is the authority‑level rationalisation for the Statement. Third, it lists discrete factors that must exist as a minimum before a reasonable hypothesis can be raised: 25 factors that apply to clinical onset of gout (s9(1)-(25)) and 26 parallel factors that apply to clinical worsening of gout (s9(26)-(51)). The factors encompass prior haematological disorders, specified drug exposures, chemotherapy, anthropometric thresholds (being overweight), quantified alcohol, meat and seafood consumption, dehydration and fasting, surgical or traumatic events in narrow time windows, transplant status, chronic kidney disease and other clinical comorbidities, and inability to obtain appropriate clinical management.

The instrument is explicit about timing and thresholds. Examples are: a continuous seven‑day course of a specified class of antihypertensive drug with the last dose within three months before clinical onset (s9(2)); daily low‑dose aspirin for two consecutive days, with last dose within 48 hours (s9(3)); consumption of at least 120 grams per week of alcohol averaged over three months (s9(7)); or at least 70 grams of alcohol within 48 hours (s9(8)). Definitions and numerical thresholds are supplied in Schedule 1 - Dictionary, including BMI formula, definitions of dehydration and chronic kidney disease, and specified drug lists.

The instrument does not itself create penalties or new statutory benefits. It is a technical evidentiary instrument used in claims processing under the VEA and MRCA framework. It also contains an internal mechanism for interaction with other Statements of Principles: where a listed factor refers to a disease or injury that is the subject of another Statement, the other Statement’s factors apply “in accordance with the terms of that Statement of Principles as in force from time to time” (s11). Practically, decision‑makers will use the factors listed here as the minimum threshold for a “reasonable hypothesis” that service could be related to gout; claimants will need to supply evidence that maps to these factors if they are to meet that threshold.

The instrument is an evidentiary grid built around three main concepts: definition of condition, enumerated causal or contributing factors, and the relationship to relevant service. Each is defined and constrained in the instrument.

Definition of the condition. “Gout” is defined for instrument purposes as a metabolic condition characterised by deposition of urate crystals in joints or tissues, generally following raised serum uric acid levels (s7(2)). Although gout attracts ICD‑10‑AM code M10, the instrument insists that the substantive meaning for claims is the text of s7(2), not the ICD code alone (s7(3)). The instrument also expressly covers “death from gout” where gout contributed to a terminal event or condition (s7(5) and Schedule 1 definition of terminal event).

Enumerated factors as the minimum evidence for a reasonable hypothesis. Section 9 is the core operational list. The RMA frames these factors as those that “must as a minimum exist before it can be said that a reasonable hypothesis has been raised” connecting gout or death from gout with relevant service (s9 introductory text). The list is bifurcated: factors 1-25 apply to the clinical onset of gout and factors 26-51 apply to clinical worsening. Many factors are duplicated across onset and worsening with near‑identical thresholds. The factors include pre‑existing medical diagnoses (haematological disorders (s9(1), s9(26)), chronic kidney disease (s9(21), s9(46)), psoriasis or psoriatic arthritis (s9(20), s9(45)), lead nephropathy (s9(19), s9(44))), pharmacological exposures (antihypertensive drug classes, low‑dose aspirin, specified drug lists, chemotherapy) and behavioural or environmental exposures (quantified alcohol intake, meat/seafood consumption, fasting, dehydration, trauma, surgery) tied to specific time windows (e.g. 48 hours, seven days, three months).

Relationship to service. Section 10 requires the listed factors to be related to the person’s relevant service (s10(1)). It additionally restricts the application of factors 26 to 51 (those concerning clinical worsening) to claims where the person’s gout was suffered or contracted before or during, but did not arise out of, the relevant service; in those circumstances the factors may support material contribution or aggravation (s10(2)). The instrument thereby distinguishes primary causation from material contribution/aggravation when service pre‑dated the onset.

Cross‑instrument references and definitions. The Schedule 1 - Dictionary supplies crucial definitional content and numeric thresholds: BMI formula, what counts as “being overweight” (BMI ≥ 25), chronic kidney disease as an abnormality present for at least three months, dyslipidaemia laboratory thresholds, definitions of dehydration and abnormal kidney structure or function, and the lists of specified drugs and drug classes (Specified List 1 and Specified List 2 differing by inclusion of febuxostat in List 2). The instrument also references ICD‑10‑AM and the Australian Standard for alcohol units (s7(4), notes under s9).

Primary persons affected are claimants to whom section 120A of the VEA or section 338 of the MRCA applies, and decision makers under those Acts (s5). The instrument was framed explicitly for veterans, members of Peacekeeping Forces, or members of the Forces under the VEA, and members under the MRCA, as the RMA’s view references those cohorts (s8). Practically, this means:

• Veterans, current or former members of the Australian Defence Force and those who served in peacekeeping or hazardous operations may rely on this Statement when lodging claims for entitlement where gout or death from gout is implicated. The instrument applies to claims within the statutory schemes referenced in s5; it is not a general public health instrument.

• Surviving dependants or estates are affected when death from gout is alleged, because the definition of death from gout includes terminal events contributed to by gout (s7(5)).

• Medical practitioners and treating clinicians will be affected insofar as their records, diagnostic labels, laboratory values, prescription records and clinical notes are the evidence used to establish the presence of any of the listed factors. The Schedule supplies specific thresholds that clinicians and forensic medical assessors will need to document and calculate (for example BMI calculation, GFR thresholds, lipid cut‑offs, time windows for exposures).

• Departmental and tribunal decision‑makers who determine entitlements under the VEA and MRCA must apply this Statement as part of the evidence base for whether a “reasonable hypothesis” connects gout or death from gout to relevant service. The instrument requires that at least one factor in s9 must exist for a reasonable hypothesis to be raised. The instrument also instructs that if a listed factor refers to another injury or disease covered by another Statement, the factors in that other Statement apply as in force from time to time (s11). That creates a coordination obligation for decision‑makers to consult multiple Statements where cross‑references occur.

• Legal representatives and advocates who prepare claims will be affected by the instrument’s precision. The numerical and temporal thresholds (for example the 48‑hour windows, three‑month averaging periods, and particular dose or duration requirements) will shape what documentary evidence is needed and what lines of medical questioning are productive.

• Pharmacists, hospitals and prescribing authorities may be indirectly affected because prescription records and pharmacy dispensing dates will be relevant for showing timing and continuity of drug exposures (for example, a seven‑day continuous course of a specified antihypertensive with last dose within three months before clinical onset, s9(2)).

The instrument is an evidentiary statement and so its principal effect is on decision‑making process rather than conferral of rights or imposition of criminal duties. Nonetheless, it creates de facto procedural duties and entitlements within the claims context by defining the minimum factors necessary to raise a “reasonable hypothesis”.

Duty to check for listed factors. For claims where gout or death from gout is in issue, decision‑makers in the VEA/MRCA process will use this Statement as the minimum checklist for a reasonable hypothesis. Section 9 expressly states that “At least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting gout or death from gout with the circumstances of a person's relevant service.” That places an operational duty on claim adjudicators to identify whether any listed factor is present in the evidence.

Duty to relate factors to relevant service. Section 10(1) requires that the existence of any factor referred to in section 9 must be related to the person’s relevant service. This is a jurisdictional constraint: identification of a factor is not alone sufficient; there must be a link between the factor and the person’s relevant service. The instrument does not prescribe how that relationship is proved; that task falls to the decision‑maker within the claims framework.

Duty to apply other Statements where relevant. Section 11 imposes a duty of coordination: if a factor in this Statement refers to an injury or disease covered by another Statement of Principles made under subsection 196B(2) of the VEA, then “the factors in that Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time.” Practically, this requires decision‑makers to consult multiple Statements and apply the then‑operative factors in the other Instruments.

Right to have the Statement applied to a claim. Claimants have the right, implicit within the VEA/MRCA claim processes, to have their claim assessed using the Statements of Principles that apply. Section 5 expressly states the instrument applies to claims to which s120A VEA or s338 MRCA applies. While the instrument itself does not create an entitlement, it governs the evidentiary assessment that will determine entitlement under those Acts.

Evidentiary duties for claimants and medical practitioners. The specific thresholds and timing requirements in s9 and Schedule 1 create duties in practice for claimants and their medical advisers to assemble documentary evidence that maps to the statutory factors: prescription records, drug dispensing dates and dosages, chemotherapy dates, laboratory results demonstrating dyslipidaemia or abnormal kidney function, BMI calculations, and contemporaneous dietary or clinical notes to substantiate alcohol, meat or seafood consumption, dehydration, fasting, trauma or surgery in the specified windows.

The Statement of Principles instrument does not itself create penalties, sanctions, or criminal offences. It is an evidentiary instrument made under the powers of subsection 196B(2) of the VEA (s3). The text contains no express enforcement mechanism, fine, or penalty provision. Its function is to provide the medical and definitional framework that must be applied in claims processing under the VEA and MRCA, and therefore enforcement of outcomes or imposition of liabilities arises through the substantive and procedural provisions of those Acts, not through this instrument.

What enforcement or consequence there is flows indirectly: the instrument sets thresholds that determine whether a “reasonable hypothesis” connecting gout or death from gout to relevant service is raised (s9). The practical consequences of whether a reasonable hypothesis is established will be determined by the procedural and merits processes of the VEA or MRCA. The instrument does not itself set decision outcomes; rather, it specifies a minimal evidentiary threshold that adjudicators use in their determinations. Therefore:

• No criminal or civil penalties are introduced by the Statement itself. The instrument contains no penalty clauses or enforcement provisions.

• Administrative consequence. The principal enforcement‑style consequence is administrative: if a claimant cannot establish the existence of any of the factors in s9, then a decision‑maker may determine that no reasonable hypothesis has been raised, which will affect entitlement decisions under the VEA and MRCA. The instrument thereby shapes administrative outcomes without creating standalone sanctions.

• Coordination with other Statements. Section 11 requires application of other Statements where factors cross‑refer. Non‑compliance with this requirement would be an administrative process or legal error in decision‑making rather than an offence actionable under the Statement.

• Repeal and supersession. The instrument repealed the prior Statement No. 30 of 2010 (s4). Where the RMA replaces Statements, the decision‑making practices of the Department and tribunals must follow the current Statements; failure to do so could be challenged through the appeal routes available under the VEA/MRCA regime, but those appeal mechanisms are not specified in this Statement.

Because the instrument is limited to specifying medical and definitional factors and makes no express provision for enforcement, the relevant enforcement architecture and remedies for decisions made under it are those provided by the VEA and MRCA and their administrative and judicial review pathways. The Statement does not identify or alter those channels.

This Statement of Principles is expressly made under the Veterans' Entitlements Act 1986 (VEA), subsection 196B(2) (s3). It applies to claims to which section 120A of the VEA or section 338 of the Military Rehabilitation and Compensation Act 2004 (MRCA) applies (s5). The instrument therefore operates as a subordinate evidentiary instrument feeding into statutory decision processes established by the VEA and MRCA, though the instrument itself does not restate or summarise those Acts.

Interaction with the VEA and MRCA. The Statement is incorporated operationally into claims under the cited provisions. The instrument does not reproduce those provisions, but its applicability is tethered to claims within the ambit of s120A VEA and s338 MRCA (s5). Where a decision under the VEA or MRCA requires a medical assessment of causal connection, the Statement provides the RMA‑approved factors to be used in deciding whether a “reasonable hypothesis” exists.

Cross‑Statement coordination. Section 11 provides an internal statutory rule for interaction with other Statements of Principles: if a factor in this instrument refers to an injury or disease covered by another Statement made under subsection 196B(2) of the VEA, then the factors in that other Statement “apply in accordance with the terms of that Statement of Principles as in force from time to time.” This is a continuity and hierarchy rule: where cross‑references arise, operational application must follow the current terms of the other Statement. That requires decision‑makers to maintain currency with multiple Statements and to reconcile overlapping or sequential factors.

Reference to clinical coding and standards. Section 7(3)-(4) notes that while gout attracts ICD‑10‑AM code M10, the meaning of gout in this Statement is the textual definition in s7(2). The instrument explicitly references the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD‑10‑AM), Tenth Edition, effective 1 July 2017, and identifies the copyright holder (s7(4)). This shows the instrument’s deference to recognised clinical classification systems while preserving the primacy of its own textual definition for claim‑assessment purposes.

Pharmaceutical lists and clinical definitions. The Schedule 1 - Dictionary defines specified drug lists (Specified List 1 and Specified List 2), specified antihypertensive drug classes, and various clinical lab thresholds (for dyslipidaemia, chronic kidney disease and so on). Those definitions will interact with other health‑related laws and standards in practice: for example, laboratory reports, prescribing records, and hospital discharge summaries produced under health privacy laws and professional obligations will be the evidence used to apply the Statement. The Statement does not conflict with those regimes; it organises evidentiary expectations specific to the VEA/MRCA claims context.

The instrument itself contains only a brief amendment history. The key historical facts recorded in the text are:

• This Statement is numbered No. 59 of 2019 and bears the date 26 April 2019 on the instrument (front matter). It commenced on 27 May 2019 (s2).

• Section 4 expressly repeals the previous Statement of Principles concerning gout No. 30 of 2010 (Federal Register of Legislation No. F2010L01046), which had been made under subsection 196B(2) of the VEA. The instrument therefore supersedes the 2010 Statement as from its commencement date.

Other than the repeal in s4 and the commencement provision in s2, the instrument contains no further amendment history or prior versions within its text. The Schedule is integral to the current instrument and supplies definitional and list changes (for example the inclusion of febuxostat in Specified List 2 but not Specified List 1). Any subsequent changes to these lists or definitions would occur through later Statements of Principles issued under the RMA’s s196B(2) power, but such later instruments are not contained within this text.

Practical implications of repeal and replacement. Where an older Statement has been repealed and superseded, decision‑makers, claimants, and advisers must establish which instrument was in force at the time relevant to the claim or event. The instrument does not specify transitional arrangements for claims underway at the time of commencement; those transitional rules will typically be governed by the VEA/MRCA processes and administrative practice. The instrument’s explicit repeal notation (s4) confirms that after commencement the 2010 Statement is no longer operative.

No amendments, revocations or modifications after commencement are recorded in this document. The instrument itself contains the authoritative content as from its commencement date until it is expressly amended or repealed in a later instrument.

Finally, the instrument’s Schedule 1 establishes the current definitional baseline , any amendment to those definitions or to the Specified Lists would effect a substantive change in how the rma’s “minimum factors” operate. The inclusion of both Specified List 1 and Specified List 2 and the differing contents (for example febuxostat appearing in List 2) indicates deliberate tailoring rather than generic carryover of prior lists, but the instrument does not provide a legislative history of why items were added or removed beyond its date and repeal statement.

The instrument does not mention any litigation, judicial determinations, or tribunal outcomes. There are no cases named or cited in the text. Consequently the instrument itself contains no litigation history to report.

What the instrument does do is create the evidentiary framework that will be used by decision‑makers under the VEA and MRCA. Challenges to decisions that apply this Statement would arise under the appeal and review mechanisms available in the VEA and MRCA regimes, or by judicial review where appropriate. However, the Statement itself does not document any such proceedings, nor does it provide guidance on remedies or appeal rights. Any litigation history relevant to the interpretation or application of this Statement would therefore exist outside the instrument and would need to be sourced from the case law and tribunal records governing VEA/MRCA appeals and judicial review. Those materials are not part of this instrument and no cases are referred to in the text.

For practitioners preparing to advise clients, that means:

• Do not expect precedent decided under this Statement to be summarised in the instrument. Any legal disputes about application, interpretation of definitional thresholds, or the weight given to particular factors will be found in the decisions of the Veterans' Review Board, Administrative Appeals Tribunal, or courts.

• When a decision maker applies this Statement and a claimant disputes that application, the dispute will be resolved through the statutory appeal channels under the VEA or MRCA and, if necessary, judicial review. The instrument itself provides only the criteria and definitions and is silent on dispute resolution.

If litigation history is required for strategic or research purposes, it must be obtained from tribunal and court databases and from the administrative records of the agencies that adjudicate VEA/MRCA claims. The Statement provides the operative text that courts and tribunals would interpret but contains no internal litigation narrative.

This Statement contains many technical details and timing thresholds that can catch claimants, practitioners and decision‑makers if they are not carefully attended to. The following are specific points where misunderstanding or incomplete evidence can be decisive, with the statutory references attached.

1. “At least one” factor required to raise a reasonable hypothesis (s9). The instrument does not require proof of multiple factors. However, it does require at least one listed factor. Failure to document any listed factor may be dispositive at the “reasonable hypothesis” stage.

2. Distinction between onset and worsening (s9; s10(2)). Sections 9(1)-(25) apply to clinical onset; 9(26)-(51) apply to clinical worsening. Critically, s10(2) restricts the application of the worsening factors to situations where the gout was suffered or contracted before or during, but did not arise out of, relevant service. Misclassifying whether the gout “arose out of” service will determine which parts of the Statement can be relied upon.

3. Time windows and “last dose” rules. Several drug and exposure factors tie to narrow time windows: e.g. drugs from Specified List 1 within 48 hours before onset (s9(4)); chemotherapy within seven days (s9(5)); antihypertensive drug classes for at least seven continuous days with the last dose within three months before onset (s9(2)). Practitioners must document prescription dates, dispensing dates and patient adherence. A gap between last dose and onset beyond the stated window may nullify the factor.

4. Small‑dose and short‑duration exposures matter. Low‑dose aspirin ≤ 325 mg for only two consecutive days before onset, with last dose within 48 hours, is a listed factor (s9(3)). That is a narrow behavioural exposure that can be overlooked in clinical histories. Similarly, fasting or dehydration for at least 24 continuous hours within 48 hours before onset is sufficient (s9(14), s9(15)).

5. Quantified dietary thresholds. The instrument uses gram quantities and averaging periods: 120 g/week of alcohol averaged for three months (s9(7)) versus 70 g of alcohol within 48 hours (s9(8)); 750 g/week of meat/offal averaged over three months (s9(9)); 300 g within 48 hours (s9(10)); 120 g/week of seafood averaged over three months (s9(11)); 120 g within 48 hours (s9(12)). These are precise and require contemporaneous dietary documentation or reliable retrospective dietary histories.

6. BMI calculation and “being overweight” (Schedule 1). “Being overweight” is defined as BMI ≥ 25 (Schedule 1). Practitioners must calculate BMI using weight and height and document the timing relative to clinical onset or worsening.

For practitioners, claimants, treating clinicians and decision‑makers, compliance means assembling and presenting evidence that maps to the instrument’s numeric, temporal and diagnostic thresholds, and ensuring the relationship to relevant service is documented. The following operational checklist is grounded in the instrument’s sections and Schedule 1 definitions.

1. Confirm applicability. Before investing in evidence collection, confirm that the claim falls within the cited statutory gateways: the claim must be one to which s120A of the VEA or s338 of the MRCA applies (s5). If a claim is outside those provisions the Statement will not be the operative instrument.

2. Establish the clinical label per s7(2). Ensure the medical record documents that the condition fits the instrument definition of gout: a metabolic condition characterised by deposition of urate crystals in joints or tissues generally following raised serum uric acid levels (s7(2)). If diagnosis rests on criteria or synovial fluid crystal identification, include those reports.

3. Demonstrate at least one factor in s9. The instrument requires at least one factor to exist as a minimum. For each candidate factor, collect the following:

   • Drug exposures. For s9(2), s9(4), s9(29) and related drug factors, obtain prescribing and dispensing records showing drug name, class, start and stop dates, dosages and whether treatment was continuous for specified durations. For antihypertensive classes, document at least seven continuous days of treatment and the last dose within three months before onset or worsening (s9(2), s9(27)). For low‑dose aspirin, document two consecutive days and last dose within 48 hours (s9(3), s9(28)). For Specified List 1 and Specified List 2 drugs, check the Schedule lists for inclusion (Schedule 1).

   • Chemotherapy. For s9(5) and s9(30), supply oncology records documenting chemotherapy dates and regimens within seven days before onset or worsening.

   • Surgery/trauma. Document operation notes or emergency records to show surgery or joint trauma occurred within 48 hours before onset or worsening (s9(18), s9(43), s9(25), s9(50)).

   • Dietary and substance thresholds. For alcohol and dietary consumption thresholds (s9(7)-(12), s9(32)-(37)), prepare contemporaneous records where possible: alcohol consumption logs, unit calculations, notes from attending clinicians, or credible witness statements. Use the Australian Standard of ten grams of alcohol per standard drink for conversions as the instrument’s note indicates (s9 notes). For meat/seafood grams, work with dietician notes or consistent contemporaneous records. For fruit juice and sugar‑sweetened drinks (s9(13), s9(38)), use consumption diaries or GP notes.